Pharmicell Co Ltd
Company Profile
Business description
Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.
Contact
12F Chungho B/D
3-2 Nonhyun-dong Gangnam-gu
Seoul135-010
KORT: +82 234960114
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
134
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,520.20 | 9.50 | 0.11% |
| CAC 40 | 7,836.28 | 37.55 | -0.48% |
| DAX 40 | 23,556.76 | 81.80 | -0.35% |
| Dow JONES (US) | 42,140.43 | 269.67 | -0.64% |
| FTSE 100 | 8,604.23 | 1.31 | 0.02% |
| HKSE | 23,640.65 | 532.38 | 2.30% |
| NASDAQ | 19,010.09 | 301.74 | 1.61% |
| Nikkei 225 | 38,128.13 | 55.13 | -0.14% |
| NZX 50 Index | 12,779.26 | 7.48 | -0.06% |
| S&P 500 | 5,886.55 | 42.36 | 0.72% |
| S&P/ASX 200 | 8,279.60 | 10.60 | 0.13% |
| SSE Composite Index | 3,403.95 | 29.08 | 0.86% |